Suppr超能文献

用于初级保健环境的肺癌筛查决策辅助工具:一项随机临床试验。

Lung Cancer Screening Decision Aid Designed for a Primary Care Setting: A Randomized Clinical Trial.

机构信息

Center for Health Equity Research and Promotion (CHERP), Michael J. Crescenz Veterans Affairs (VA) Medical Center, Philadelphia, Pennsylvania.

Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.

出版信息

JAMA Netw Open. 2023 Aug 1;6(8):e2330452. doi: 10.1001/jamanetworkopen.2023.30452.

Abstract

IMPORTANCE

Guidelines recommend shared decision-making prior to initiating lung cancer screening (LCS). However, evidence is lacking on how to best implement shared decision-making in clinical practice.

OBJECTIVE

To evaluate the impact of an LCS Decision Tool (LCSDecTool) on the quality of decision-making and LCS uptake.

DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial enrolled participants at Veteran Affairs Medical Centers in Philadelphia, Pennsylvania; Milwaukee, Wisconsin; and West Haven, Connecticut, from March 18, 2019, to September 29, 2021, with follow-up through July 18, 2022. Individuals aged 55 to 80 years with a smoking history of at least 30 pack-years who were current smokers or had quit within the past 15 years were eligible to participate. Individuals with LCS within 15 months were excluded. Of 1047 individuals who were sent a recruitment letter or had referred themselves, 140 were enrolled.

INTERVENTION

A web-based patient- and clinician-facing LCS decision support tool vs an attention control intervention.

MAIN OUTCOME AND MEASURES

The primary outcome was decisional conflict at 1 month. Secondary outcomes included decisional conflict immediately after intervention and 3 months after intervention, knowledge, decisional regret, and anxiety immediately after intervention and 1 and 3 months after intervention and LCS by 6 months.

RESULTS

Of 140 enrolled participants (median age, 64.0 [IQR, 61.0-69.0] years), 129 (92.1%) were men and 11 (7.9%) were women. Of 137 participants with data available, 75 (53.6%) were African American or Black and 62 (44.3%) were White; 4 participants (2.9%) also reported Hispanic or Latino ethnicity. Mean decisional conflict score at 1 month did not differ between the LCSDecTool and control groups (25.7 [95% CI, 21.4-30.1] vs 29.9 [95% CI, 25.6-34.2], respectively; P = .18). Mean LCS knowledge score was greater in the LCSDecTool group immediately after intervention (7.0 [95% CI, 6.3-7.7] vs 4.9 [95% CI, 4.3-5.5]; P < .001) and remained higher at 1 month (6.3 [95% CI, 5.7-6.8] vs 5.2 [95% CI, 4.5-5.8]; P = .03) and 3 months (6.2 [95% CI, 5.6-6.8] vs 5.1 [95% CI, 4.4-5.8]; P = .01). Uptake of LCS was greater in the LCSDecTool group at 6 months (26 of 69 [37.7%] vs 15 of 71 [21.1%]; P = .04).

CONCLUSIONS AND RELEVANCE

In this randomized clinical trial of an LCSDecTool compared with attention control, no effect on decisional conflict occurred at 1 month. The LCSDecTool used in the primary care setting did not yield a significant difference in decisional conflict. The intervention led to greater knowledge and LCS uptake. These findings can inform future implementation strategies and research in LCS shared decision-making.

TRIAL REGISTRATION

ClinicalTrials.gov Identifier: NCT02899754.

摘要

重要性

指南建议在进行肺癌筛查(LCS)之前进行共同决策。然而,目前缺乏关于如何在临床实践中最好地实施共同决策的证据。

目的

评估 LCS 决策工具(LCSDecTool)对决策质量和 LCS 采用率的影响。

设计、地点和参与者:这是一项随机临床试验,招募了宾夕法尼亚州费城、威斯康星州密尔沃基和康涅狄格州西黑文的退伍军人事务医疗中心的参与者,招募时间为 2019 年 3 月 18 日至 2021 年 9 月 29 日,随访时间至 2022 年 7 月 18 日。符合以下条件的年龄在 55 至 80 岁之间、吸烟史至少 30 包年且目前仍在吸烟或在过去 15 年内已戒烟的个体有资格参加。在过去 15 个月内接受过 LCS 的个体被排除在外。在收到招募信或自行推荐的 1047 名个体中,有 140 名被纳入研究。

干预措施

基于网络的患者和临床医生的 LCS 决策支持工具与对照干预措施。

主要结果和措施

主要结局是 1 个月时的决策冲突。次要结局包括干预后即刻和干预后 3 个月的决策冲突、知识、决策后悔、焦虑,以及干预后即刻和 1 个月和 3 个月的焦虑,以及 6 个月时的 LCS。

结果

在纳入的 140 名参与者(中位数年龄,64.0 [IQR,61.0-69.0] 岁)中,129 名(92.1%)为男性,11 名(7.9%)为女性。在 137 名有数据可用的参与者中,75 名(53.6%)为非裔美国人或黑人,62 名(44.3%)为白人;4 名参与者(2.9%)还报告了西班牙裔或拉丁裔种族。在 1 个月时,LCSDecTool 组和对照组的决策冲突评分没有差异(分别为 25.7 [95% CI,21.4-30.1] 和 29.9 [95% CI,25.6-34.2];P = .18)。干预后即刻,LCSDecTool 组的 LCS 知识评分较高(7.0 [95% CI,6.3-7.7] vs 4.9 [95% CI,4.3-5.5];P < .001),并且在 1 个月时(6.3 [95% CI,5.7-6.8] vs 5.2 [95% CI,4.5-5.8];P = .03)和 3 个月时(6.2 [95% CI,5.6-6.8] vs 5.1 [95% CI,4.4-5.8];P = .01)也更高。在 6 个月时,LCSDecTool 组的 LCS 采用率更高(26/69 [37.7%] vs 15/71 [21.1%];P = .04)。

结论和相关性

在这项与对照相比的 LCSDecTool 随机临床试验中,在 1 个月时没有出现决策冲突的影响。在初级保健环境中使用的 LCSDecTool 并没有在决策冲突方面产生显著差异。该干预措施导致了更多的知识和 LCS 采用。这些发现可以为未来的 LCS 共同决策实施策略和研究提供信息。

试验注册

ClinicalTrials.gov 标识符:NCT02899754。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/583f/10469267/9ebe9d62d1c9/jamanetwopen-e2330452-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验